Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With Lymphoma

Inclusion Criteria: * Adult patients ≥ 18 years old diagnosed with any type of lymphoma. * Receiving chemotherapy-based treatment known to cause thrombocytopenia. Eligibility is limited to regimens with a 21-day cycle. Previous single-agent anti-CD20 antibody or radiotherapy will not count as a line of treatment. Eligible regimens include those based on a platinum backbone (e.g. ICE, DHAX, DHAP, GemOx, GDP, ESHAP), those based on a doxorubicin backbone (e.g. CHOP, CDOP, HyperCVAD, BEACOPP) or on a high-dose cytarabine backbone (e.g.HiDAC). Of note, treatment programs which involve sequential administration of two or more regimens (e.g. CHOP-\>ICE or CHOP-DHAX) are eligible as long as the patient is planned for at least two more cycles of the regimen on which the CIT was initially observed. Regimens with inherent dose-adjustments by blood counts (e.g. da-EPOCH) are ineligible unless the treating oncologist is not planning to increase treatment doses on subsequent cycles. * History of a severe treatment-related thrombocytopenia during the most recent cycle of treatment, as defined by one or more of the following criteria: * PLT \< 50,000 on day 1 (- 2 days) of the subsequent treatment cycle. * Grade 4 thrombocytopenia, defined as PLT \<25,000 cells/mcl and/or transfusion for thrombocytopenia or bleeding. Need for PLT transfusion in order to meet minimal PLT criteria for invasive procedures will not count for eligibility. * Patient is planned for at least one more cycle of…